Conexiant’s news site is now MDSpire News. Learn more
Advertisement
OM-89 may curb postantibiotic E coli regrowth
Lysosomal activation and increased intracellular antibiotic accumulation accompanied reduced bacterial regrowth across mouse and human bladder epithelial models.
Clinical Report: OM-89 may curb postantibiotic E coli regrowth
Overview
OM-89 enhances antimicrobial defenses in bladder epithelial cells, reducing regrowth of uropathogenic E. coli after antibiotic treatment. The study demonstrated that OM-89 improves lysosomal function and intracellular antibiotic accumulation, leading to decreased bacterial burden during and after antibiotic therapy.
Background
Recurrent urinary tract infections (rUTIs) pose a significant clinical challenge, often requiring repeated antibiotic courses that can lead to resistance. OM-89, an orally administered bacterial lysate, has been investigated for its potential to enhance the body's natural defenses against uropathogenic E. coli. Understanding its mechanisms could inform better management strategies for rUTIs.
Data Highlights
No numerical data available in the source material.
Key Findings
OM-89 did not show direct antibacterial activity during initial infection phases in mouse bladder organoids.
During antibiotic treatment, OM-89 reduced bacterial burden and postantibiotic regrowth across multiple exposure regimens.
Increased intracellular accumulation of antibiotics was observed in differentiated mouse bladder epithelial cells treated with OM-89.
OM-89 significantly reduced bacterial regrowth in human bladder organoids after antibiotic treatment.
Transcriptomic profiling indicated that lysosomal pathways were strongly induced during OM-89 treatment.
Pharmacologic inhibition of lysosomal acidification abolished the reduction in postantibiotic bacterial regrowth associated with OM-89.
Clinical Implications
The findings indicate that OM-89 may enhance the efficacy of antibiotic treatment and reduce the risk of bacterial regrowth.
Conclusion
OM-89 enhances the control of uropathogenic E. coli regrowth post-antibiotic treatment through mechanisms involving lysosomal function.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
